title: Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II).
abstract: To evaluate the feasibility, effectiveness, and long-term bowel function of preoperative hyperfractionated accelerated radiotherapy in primary resectable rectal cancer. A total of 184 consecutive patients (median age 65 years, male : female=2 : 1) with clinical T3Nx rectal adenocarcinoma received preoperative pelvic radiation therapy with single fractions of 2.5 Gy twice daily (interval 6 h between fractions) to a total dose of 25 Gy within 1 week. Surgery was conducted the following week. Postoperative histology revealed UICC stage I in 33%, stage II in 26%, stage III in 34%, and stage IV in 7% of the patients. Median follow-up was 43 months (53 months for surviving patients). The actuarial 4-year-local-recurrence rate was 2.1%, overall recurrence 23%. Disease-specific and disease-free survivals at 4 years (excluding stage IV) were 82 and 69%, respectively. Overall survival for 4 years was 68%. Postoperative mortality was 0.5% (one patient), early anastomotic leakage occurred in 11.4%, and anastomotic stenosis requiring treatment in 6%, of 132 patients with primary anastomosis. Seven of 184 patients (3.8%) died of abdominal complications, all within the first year. Bowel function was satisfactory after more than 5 years. Local control in primarily resectable rectal cancer after 10 x 2.5 Gy is excellent, warranting further evaluation of this treatment.
authors.affiliation: Department of Radiotherapy and Radiobiology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. joachim.widder@akhwien.at
authors.forename: J
authors.initials: J
authors.lastname: Widder
authors.forename: F
authors.initials: F
authors.lastname: Herbst
authors.forename: W
authors.initials: W
authors.lastname: Dobrowsky
authors.forename: R
authors.initials: R
authors.lastname: Schmid
authors.forename: B
authors.initials: B
authors.lastname: Pokrajac
authors.forename: B
authors.initials: B
authors.lastname: Jech
authors.forename: C
authors.initials: C
authors.lastname: Chiari
authors.forename: A
authors.initials: A
authors.lastname: Stift
authors.forename: A
authors.initials: A
authors.lastname: Maier
authors.forename: J
authors.initials: J
authors.lastname: Karner-Hanusch
authors.forename: B
authors.initials: B
authors.lastname: Teleky
authors.forename: F
authors.initials: F
authors.lastname: Wrba
authors.forename: R
authors.initials: R
authors.lastname: Jakesz
authors.forename: R
authors.initials: R
authors.lastname: Poetter
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000714:Anastomosis, Surgical; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local; D012004:Rectal Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D016896:Treatment Outcome